BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia (2023)
Source: Biochemical Journal. Unidades: FCFRP, ICB
Subjects: IMUNOLOGIA, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, PROTEÍNAS QUINASES
ABNT
BRUMATTI, Gabriela et al. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal, v. 480, p. 161–176, 2023Tradução . . Disponível em: https://doi.org/10.1042/BCJ20210608. Acesso em: 26 ago. 2024.APA
Brumatti, G., Kaloni, D., Castro, F. A. de, & Amarante-Mendes, J. G. P. (2023). BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal, 480, 161–176. doi:10.1042/BCJ20210608NLM
Brumatti G, Kaloni D, Castro FA de, Amarante-Mendes JGP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia [Internet]. Biochemical Journal. 2023 ; 480 161–176.[citado 2024 ago. 26 ] Available from: https://doi.org/10.1042/BCJ20210608Vancouver
Brumatti G, Kaloni D, Castro FA de, Amarante-Mendes JGP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia [Internet]. Biochemical Journal. 2023 ; 480 161–176.[citado 2024 ago. 26 ] Available from: https://doi.org/10.1042/BCJ20210608